Late Restenosis Following Placement of a Sirolimus Eluting Stent for In-Stent Restenosis
Drug eluting stents (DES) are rapidly replacing intravascular brachytherapy for the treatment of bare metal in-stent restenosis (ISR). To date, there are no long-term follow up data supporting this practise. We report symptomatic repeat in-stent restenosis occurring 27 months after sirolimus eluting stent deployment for de novo in-stent restenosis. This case suggests that in a subgroup of patients with ISR, as with brachytherapy, the drug eluting stent may be simply delaying rather than inhibiting the restenotic process.
Keywords: Drug eluting stent, In-stent restenosis
To access this article, please choose from the options below
PII: S1443-9506(06)00190-9
doi:10.1016/j.hlc.2006.08.004
© 2006 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier Inc. All rights reserved.
